Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders

US9492480B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9492480-B2
Application numberUS-201113640843-A
CountryUS
Kind codeB2
Filing dateApr 12, 2011
Priority dateApr 12, 2010
Publication dateNov 15, 2016
Grant dateNov 15, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

In accordance with the present disclosure there are provided iron oxide nanoparticles for use in the treatment of non-infectious inflammatory disorders. Also provided by the present disclosure is a method of treatment of non-infectious inflammatory disorders making use of such particles, pharmaceutical compositions and kits comprising such particles.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for treating myocardial infarction in a human subject suffering from myocardial infarction, the method comprising: administering to the subject in need an amount of an active agent effective to treat myocardial infarction, said active agent being iron oxide nanoparticles, wherein said method does not include a step of magnetic resonance imaging of myocardial infarction using iron oxide particles. 2. The method of claim 1 , wherein the iron oxide nanoparticles are in naked form, surface modified, or formulated within a carrier. 3. The method of claim 1 , wherein the iron comprises one or both of ferric iron (Fe 3+ ) and ferrous iron (Fe 2+ ). 4. The method of claim 1 , wherein the iron oxide is selected from the group consisting of magnetic iron oxide, ferromagnetic iron oxide, ferrimagnetic iron oxide and anti-ferromagnetic iron oxide. 5. The method of claim 1 , wherein the iron oxide is superparamagnetic iron oxide. 6. The method of claim 1 , wherein the iron oxide nanoparticles are modified with an organic material selected from the group consisting of small molecules, surfactants, polymers and biomolecules. 7. The method of claim 1 , wherein the iron oxide nanoparticles are modified with an inorganic material selected from the group consisting of silica, metal substance, nonmetal elementary substance, metal oxides and metal sulfides. 8. The method of claim 1 , wherein the iron oxide nanoparticles are in the form selected from the group consisting of an iron oxide core within a shell of organic or inorganic material; a mosaic form; a core of organic or inorganic material within a shell of iron oxide; a shell-core-shell form; and a bi-functional dumbbell form. 9. The method of claim 1 , wherein the iron oxide nanoparticles are embedded within a polymeric shell coating or encapsulated within a core or a lipid-based vesicle. 10. The method of claim 9 , wherein the iron oxide nanoparticles are encapsulated within liposomes. 11. The method of claim 10 , wherein the liposomes are multilamellar vesicles (MLV). 12. The method of claim 10 , comprising a targeting moiety for targeting the liposome to a target site. 13. The method of claim 12 , wherein the targeting moiety is hyaluronic acid. 14. The method of claim 9 , wherein the polymeric shell coating comprises polymers selected from the group consisting of polysaccharide, polyethyleneglycol, dextran, siloxanes, and carboxydextran. 15. The method of claim 1 , wherein the iron oxide nanoparticles have a diameter of between 1 nm to 200 nm. 16. The method of claim 1 , wherein the iron oxide nanoparticles are administered by injection in combination with a pharmaceutical carrier.

Assignees

Inventors

Classifications

  • Drug delivery · CPC title

  • Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant · CPC title

  • Nanoparticle, i.e. structure having three dimensions of 100 nm or less · CPC title

  • with organic macromolecular compounds · CPC title

  • Oxides; Hydroxides {(C01G49/0018 takes precedence)} · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9492480B2 cover?
In accordance with the present disclosure there are provided iron oxide nanoparticles for use in the treatment of non-infectious inflammatory disorders. Also provided by the present disclosure is a method of treatment of non-infectious inflammatory disorders making use of such particles, pharmaceutical compositions and kits comprising such particles.
Who is the assignee on this patent?
Leor Jonathan, Ben-Mordechai Tamar, Adutler-Lieber Shimrit, and 5 more
What technology area does this patent fall under?
Primary CPC classification A61K33/26. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).